Dennis Cotter

Summary

Publications

  1. ncbi request reprint The effect of epoetin dose on hematocrit
    D Cotter
    Medical Technology and Practice Patterns Institute, 4733 Bethesda Avenue, Suite 510, Bethesda, Maryland 20814, USA
    Kidney Int 73:347-53. 2008
  2. ncbi request reprint Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients
    Dennis J Cotter
    Medical Technology and Practice Patterns Institute, Inc, 4733 Bethesda Avenue, Suite 510, Bethesda, MD 20814, USA
    J Clin Epidemiol 57:1086-95. 2004
  3. ncbi request reprint Translating epoetin research into practice: the role of government and the use of scientific evidence
    Dennis Cotter
    Medical Technology and Practice Patterns Institute Inc, Bethesda, Maryland, USA
    Health Aff (Millwood) 25:1249-59. 2006
  4. pmc Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States
    Yi Zhang
    Medical Technology and Practice Patterns Institute, Bethesda, Maryland 20814, USA
    Clin J Am Soc Nephrol 4:638-44. 2009
  5. ncbi request reprint Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis: the authors respond
    Mae Thamer
    Medical Technology and Practice Patterns Institute, Bethesda, Maryland 20814, USA
    Am J Kidney Dis 50:538-41. 2007
  6. ncbi request reprint Factors influencing route of administration for epoetin treatment among hemodialysis patients in the United States
    Mae Thamer
    Medical Technology and Practice Patterns Institute, Bethesda, MD, USA
    Am J Kidney Dis 48:77-87. 2006
  7. ncbi request reprint Epoetin requirements predict mortality in hemodialysis patients
    Yi Zhang
    Medical Technology and Practice Patterns Institute, Bethesda, MD 20814, USA
    Am J Kidney Dis 44:866-76. 2004
  8. ncbi request reprint Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis
    Mae Thamer
    Medical Technology and Practice Patterns Institute, Bethesda, MD 20814, USA
    JAMA 297:1667-74. 2007
  9. pmc High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes
    Yi Zhang
    Medical Technology and Practice Patterns Institute, 4733 Bethesda Avenue, Bethesda, MD 20814, USA
    Kidney Int 80:663-9. 2011
  10. pmc Organizational status of dialysis facilities and patient outcome: does higher injectable medication use mediate increased mortality?
    Yi Zhang
    Medical Technology and Practice Patterns Institute, Bethesda, MD 20814, USA
    Health Serv Res 48:949-71. 2013

Research Grants

Detail Information

Publications13

  1. ncbi request reprint The effect of epoetin dose on hematocrit
    D Cotter
    Medical Technology and Practice Patterns Institute, 4733 Bethesda Avenue, Suite 510, Bethesda, Maryland 20814, USA
    Kidney Int 73:347-53. 2008
    ....
  2. ncbi request reprint Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients
    Dennis J Cotter
    Medical Technology and Practice Patterns Institute, Inc, 4733 Bethesda Avenue, Suite 510, Bethesda, MD 20814, USA
    J Clin Epidemiol 57:1086-95. 2004
    ..To evaluate the use of hematocrit as a surrogate end point for survival among end-stage renal disease (ESRD) patients treated with epoetin...
  3. ncbi request reprint Translating epoetin research into practice: the role of government and the use of scientific evidence
    Dennis Cotter
    Medical Technology and Practice Patterns Institute Inc, Bethesda, Maryland, USA
    Health Aff (Millwood) 25:1249-59. 2006
    ..Were the right choices made? Epoetin showcases the risk and benefit conundrum created when evidentiary standards are relaxed. Our review concludes with broad-based policy recommendations for the newly implemented Medicare Part D program...
  4. pmc Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States
    Yi Zhang
    Medical Technology and Practice Patterns Institute, Bethesda, Maryland 20814, USA
    Clin J Am Soc Nephrol 4:638-44. 2009
    ....
  5. ncbi request reprint Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis: the authors respond
    Mae Thamer
    Medical Technology and Practice Patterns Institute, Bethesda, Maryland 20814, USA
    Am J Kidney Dis 50:538-41. 2007
  6. ncbi request reprint Factors influencing route of administration for epoetin treatment among hemodialysis patients in the United States
    Mae Thamer
    Medical Technology and Practice Patterns Institute, Bethesda, MD, USA
    Am J Kidney Dis 48:77-87. 2006
    ..Despite this disparity, few studies have examined factors associated with route of epoetin administration in hemodialysis patients...
  7. ncbi request reprint Epoetin requirements predict mortality in hemodialysis patients
    Yi Zhang
    Medical Technology and Practice Patterns Institute, Bethesda, MD 20814, USA
    Am J Kidney Dis 44:866-76. 2004
    ..Escalating epoetin doses often are used to overcome epoetin resistance. The objective of this study is to examine the relationship between epoetin dose requirements and mortality...
  8. ncbi request reprint Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis
    Mae Thamer
    Medical Technology and Practice Patterns Institute, Bethesda, MD 20814, USA
    JAMA 297:1667-74. 2007
    ..The type of facility (profit, chain, and affiliation status) at which a patient receives dialysis might affect epoetin dosing patterns and has implications for future epoetin policies...
  9. pmc High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes
    Yi Zhang
    Medical Technology and Practice Patterns Institute, 4733 Bethesda Avenue, Bethesda, MD 20814, USA
    Kidney Int 80:663-9. 2011
    ..Our findings support a Food and Drug Administration advisory recommending that the lowest possible ESA dose be used to treat hemodialysis patients...
  10. pmc Organizational status of dialysis facilities and patient outcome: does higher injectable medication use mediate increased mortality?
    Yi Zhang
    Medical Technology and Practice Patterns Institute, Bethesda, MD 20814, USA
    Health Serv Res 48:949-71. 2013
    ..Examine the mediating effect of injectable drugs in the relationship between dialysis facility organizational status and patient mortality...
  11. pmc Influence of safety warnings on ESA prescribing among dialysis patients using an interrupted time series
    Mae Thamer
    Medical Technology and Practice Patterns Institute, 5272 River Road, Suite 500, Bethesda, MD 20816, USA
    BMC Nephrol 14:172. 2013
    ..The goal is to determine if a change in ESA use was observed following the warning among US dialysis patients...
  12. pmc The effect of dialysis chains on mortality among patients receiving hemodialysis
    Yi Zhang
    Medical Technology and Practice Patterns Institute, 4733 Bethesda Ave, Bethesda, MD 20814, USA
    Health Serv Res 46:747-67. 2011
    ..To examine the association between dialysis facility chain affiliation and patient mortality...
  13. pmc Prednisone, lupus activity, and permanent organ damage
    Mae Thamer
    Medical Technology and Practice Patterns Institute, Bethesda, MD 20814, USA
    J Rheumatol 36:560-4. 2009
    ..To estimate the effect of corticosteroids (prednisone dose) on permanent organ damage among persons with systemic lupus erythematosus (SLE)...

Research Grants2

  1. Epoetin Therapy and Survival of Hemodialysis Patients
    Dennis Cotter; Fiscal Year: 2005
    ..Our goal is to ensure that treatment patterns for this high-risk population are rationally based to provide the patients with the best possibilities for survival. ..
  2. Epoetin Therapy and Survival of Hemodialysis Patients
    Dennis Cotter; Fiscal Year: 2006
    ..Our goal is to insure that treatment !patterns for this high-risk population are rationally based to provided the patients with the best possibilities for survival. ..